AU2014336928B2 - Genetic markers for antipsychotic induced weight gain and methods for use thereof - Google Patents

Genetic markers for antipsychotic induced weight gain and methods for use thereof Download PDF

Info

Publication number
AU2014336928B2
AU2014336928B2 AU2014336928A AU2014336928A AU2014336928B2 AU 2014336928 B2 AU2014336928 B2 AU 2014336928B2 AU 2014336928 A AU2014336928 A AU 2014336928A AU 2014336928 A AU2014336928 A AU 2014336928A AU 2014336928 B2 AU2014336928 B2 AU 2014336928B2
Authority
AU
Australia
Prior art keywords
subject
weight gain
seq
polymorphisms
allele
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014336928A
Other languages
English (en)
Other versions
AU2014336928A1 (en
Inventor
James L. Kennedy
Daniel J. Mueller
Clement C. Zai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre for Addiction and Mental Health
Original Assignee
Centre for Addiction and Mental Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre for Addiction and Mental Health filed Critical Centre for Addiction and Mental Health
Publication of AU2014336928A1 publication Critical patent/AU2014336928A1/en
Application granted granted Critical
Publication of AU2014336928B2 publication Critical patent/AU2014336928B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
AU2014336928A 2013-10-17 2014-10-17 Genetic markers for antipsychotic induced weight gain and methods for use thereof Ceased AU2014336928B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361892094P 2013-10-17 2013-10-17
US61/892,094 2013-10-17
PCT/CA2014/051000 WO2015054792A1 (en) 2013-10-17 2014-10-17 Genetic markers for antipsychotic induced weight gain and methods for use thereof

Publications (2)

Publication Number Publication Date
AU2014336928A1 AU2014336928A1 (en) 2016-05-12
AU2014336928B2 true AU2014336928B2 (en) 2020-07-16

Family

ID=52827506

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014336928A Ceased AU2014336928B2 (en) 2013-10-17 2014-10-17 Genetic markers for antipsychotic induced weight gain and methods for use thereof

Country Status (12)

Country Link
US (1) US10301678B2 (https=)
EP (2) EP3058106B1 (https=)
JP (1) JP6524073B2 (https=)
KR (1) KR102252926B1 (https=)
CN (1) CN106029901A (https=)
AU (1) AU2014336928B2 (https=)
CA (1) CA2943951C (https=)
ES (1) ES2728072T3 (https=)
IL (1) IL245159B (https=)
PT (1) PT3058106T (https=)
SG (1) SG11201602998QA (https=)
WO (1) WO2015054792A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210033619A1 (en) * 2018-02-09 2021-02-04 Metabolomic Diagnostics Limited Methods of predicting pre term birth from preeclampsia using metabolic and protein biomarkers
CN110317868B (zh) * 2019-08-09 2020-05-19 新疆医科大学第二附属医院 一种基于多基因组合交互作用预测二代抗精神病药物治疗精神分裂症致体重增加分析方法
CN117547526A (zh) * 2023-10-24 2024-02-13 首都医科大学附属北京朝阳医院 γ-氨基丁酸GABA在制备防治奥氮平诱发的不良反应药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003039234A2 (en) * 2001-11-06 2003-05-15 David Pickar Pharmacogenomics-based system for clinical applications

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
JP4071277B2 (ja) 1993-11-12 2008-04-02 ピーエイチアールアイ・プロパティーズ・インコーポレーテッド 核酸検出用ハイブリダイゼーションプローブ、共通ステム、方法およびキット
US8012718B2 (en) 2006-03-31 2011-09-06 Genomas, Inc. Physiogenomic method for predicting diabetes and metabolic syndromes induced by psychotropic drugs
US20070292962A1 (en) * 2006-04-10 2007-12-20 Duke University Methods and compositions for genetic markers for autism
US7795033B2 (en) 2007-03-19 2010-09-14 The United States Of America As Represented By The Department Of Health And Human Services Methods to predict the outcome of treatment with antidepressant medication
US8476012B2 (en) 2008-04-18 2013-07-02 Genomas, Inc. Physiogenomic method for predicting metabolic and cardiovascular side effects of thiazolidinediones
US8355927B2 (en) 2010-11-05 2013-01-15 Genomind, Llc Neuropsychiatric test reports
JP2015501652A (ja) 2011-12-14 2015-01-19 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ Ｇａｂｒ−ａ２診断

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003039234A2 (en) * 2001-11-06 2003-05-15 David Pickar Pharmacogenomics-based system for clinical applications

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BAUER, L.O. ET AL., "GABRA2 genotype, impulsivity and body mass", AM. J. ADDICT., (2012), vol. 21, pages 404 - 410 *

Also Published As

Publication number Publication date
IL245159A0 (en) 2016-06-30
CA2943951A1 (en) 2015-04-23
US20160237499A1 (en) 2016-08-18
CA2943951C (en) 2022-05-31
JP2016534715A (ja) 2016-11-10
CN106029901A (zh) 2016-10-12
IL245159B (en) 2020-10-29
EP3058106A1 (en) 2016-08-24
SG11201602998QA (en) 2016-05-30
EP3561076A1 (en) 2019-10-30
KR102252926B1 (ko) 2021-05-20
JP6524073B2 (ja) 2019-06-05
US10301678B2 (en) 2019-05-28
KR20160098188A (ko) 2016-08-18
PT3058106T (pt) 2019-05-30
ES2728072T3 (es) 2019-10-22
EP3058106B1 (en) 2019-02-27
WO2015054792A1 (en) 2015-04-23
EP3058106A4 (en) 2017-06-07

Similar Documents

Publication Publication Date Title
Hu et al. Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder
Martucci et al. N-methyl-D-aspartate receptor NR2B subunit gene GRIN2B in schizophrenia and bipolar disorder: Polymorphisms and mRNA levels
Anitha et al. Genetic analyses of roundabout (ROBO) axon guidance receptors in autism
Wang et al. The—1019 C/G polymorphism of the 5-HT1A receptor gene is associated with negative symptom response to risperidone treatment in schizophrenia patients
O'Donovan et al. Analysis of 10 independent samples provides evidence for association between schizophrenia and a SNP flanking fibroblast growth factor receptor 2
AU2015222658B2 (en) Compositions and methods for the treatment and prevention of antipsychotic medication-induced weight gain
Seneviratne et al. Susceptibility locus in neurokinin-1 receptor gene associated with alcohol dependence
Proudnikov et al. Association of polymorphisms of the cannabinoid receptor (CNR1) and fatty acid amide hydrolase (FAAH) genes with heroin addiction: impact of long repeats of CNR1
Wong et al. Association between schizophrenia and the syntaxin 1A gene
US10435748B2 (en) Genetic markers associated with suicide risk and methods of use thereof
AU2014336928B2 (en) Genetic markers for antipsychotic induced weight gain and methods for use thereof
AU2014336928A1 (en) Genetic markers for antipsychotic induced weight gain and methods for use thereof
Ingason et al. No significant association of the 5′ end of neuregulin 1 and schizophrenia in a large Danish sample
Liu et al. The YWHAE gene confers risk to major depressive disorder in the male group of Chinese Han population
CA2664366C (en) Slc1a1 antipsychotic drug response markers
HK1224705B (en) Genetic markers for antipsychotic induced weight gain and methods for use thereof
HK1224705A1 (en) Genetic markers for antipsychotic induced weight gain and methods for use thereof
You et al. Lack of association between BDNF Val66Met gene polymorphism and late-onset depression in a Chinese Han population
Zai et al. Weak association of the platelet-derived growth factor beta (PDGFB) and PDGF receptor beta (PDGFRB) genes with schizophrenia and schizoaffective disorder
US20070048767A1 (en) Marker for a Psychosis or a Mood Disorder
Zhang et al. Genetics and Pharmacogenetics of Schizophrenia: Recent Progress.
CA2517218A1 (en) Marker for psychosis or mood disorder

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired